DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced a strategic relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing new Dendrite solutions on the Microsoft software platform. Dendrite�s pharmaceutical expertise � coupled with Microsoft�s technologies in business intelligence (BI) and performance management � will produce solutions to enable pharmaceutical companies to reach prescribers and patients more effectively. Dendrite will develop its solutions on a range of Microsoft products, including Microsoft SQL Server 2005, Windows Vista and Windows Mobile. As part of this relationship, Dendrite will also participate in Microsoft�s Technology Adoption Program (TAP) which seeks to obtain real-world customer feedback on Microsoft pre-release products. In turn, Microsoft will work closely with Dendrite�s R&D efforts to enable faster development cycles of life science-specific solutions that give companies a competitive advantage. �As the global pharmaceutical industry continues to rapidly evolve, it creates a unique set of circumstances that require companies to respond quickly, reliably and efficiently,� said Subhash Vaid, Dendrite vice president of product marketing. �We�re optimistic that Dendrite�s vast pharmaceutical industry experience and Microsoft�s strength in technology will lead to the creation of a whole new set of rich solutions that will cater to these needs.� �Pharmaceutical companies are faced with the need to communicate directly to consumers as well as physicians in new ways, while adding savings to the bottom line,� said Paul Mattes, industry solutions director, U.S. Pharmaceutical and Life Sciences Vertical Group, Microsoft. �This expanded relationship will allow companies to benefit from Dendrite�s pharmaceutical expertise, while leveraging their existing IT investments with Microsoft�s familiar and easy-to-use technology.� Dendrite�s strategic decision in July to make its flagship sales force effectiveness solution Mobile IntelligenceTM available on Microsoft SQL Server 2005 was a first step in the relationship aimed at providing life science customers with additional options that could result in a lower total cost of ownership. As a result of this collaboration, the first application is expected to be available during the first quarter of 2007 in the United States and Japan. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company�s clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements. Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced a strategic relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing new Dendrite solutions on the Microsoft software platform. Dendrite's pharmaceutical expertise - coupled with Microsoft's technologies in business intelligence (BI) and performance management - will produce solutions to enable pharmaceutical companies to reach prescribers and patients more effectively. Dendrite will develop its solutions on a range of Microsoft products, including Microsoft SQL Server 2005, Windows Vista and Windows Mobile. As part of this relationship, Dendrite will also participate in Microsoft's Technology Adoption Program (TAP) which seeks to obtain real-world customer feedback on Microsoft pre-release products. In turn, Microsoft will work closely with Dendrite's R&D efforts to enable faster development cycles of life science-specific solutions that give companies a competitive advantage. "As the global pharmaceutical industry continues to rapidly evolve, it creates a unique set of circumstances that require companies to respond quickly, reliably and efficiently," said Subhash Vaid, Dendrite vice president of product marketing. "We're optimistic that Dendrite's vast pharmaceutical industry experience and Microsoft's strength in technology will lead to the creation of a whole new set of rich solutions that will cater to these needs." "Pharmaceutical companies are faced with the need to communicate directly to consumers as well as physicians in new ways, while adding savings to the bottom line," said Paul Mattes, industry solutions director, U.S. Pharmaceutical and Life Sciences Vertical Group, Microsoft. "This expanded relationship will allow companies to benefit from Dendrite's pharmaceutical expertise, while leveraging their existing IT investments with Microsoft's familiar and easy-to-use technology." Dendrite's strategic decision in July to make its flagship sales force effectiveness solution Mobile Intelligence(TM) available on Microsoft SQL Server 2005 was a first step in the relationship aimed at providing life science customers with additional options that could result in a lower total cost of ownership. As a result of this collaboration, the first application is expected to be available during the first quarter of 2007 in the United States and Japan. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.